NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/11/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,294.39 mln
Float32.38 mln
Earnings Date11/11/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
50.82
Transformational upside
Relative Strength
10
/ 100
Significantly lagging
Debt / Equity
0.02
Debt-free
ROE
-46.92
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Tyra Biosciences is a US-based clinical-stage company focused on developing targeted treatments that work with a specific protein receptor involved in cell growth, known as FGFR. The company uses its proprietary drug design platform to anticipate genetic mutations and build medicines that address both cancer and inherited conditions. Its pipeline includes treatments currently in clinical trials for bladder cancer, bile duct cancer, liver cancer, and a range of bone growth disorders. Founded in 2018 and based in Carlsbad, California, Tyra is working to advance a new generation of precisely engineered therapies.
